However, a decrease in IL-6 levels was observed with an increase in the number of treatment cycles, from T1 to T3, even though no statistical significance (p > 0.05) was found between these time points, suggesting a heterogeneity between patients at T1 that decreases with the increasing number of Nivolumab cycles in melanoma patients (Figure 2). The gene discussed is IL6; the disease is melanoma.